Log in / Register Soon
Official Education Partner of the Delhi Medicos Premier League — free question bank for every player and college
SN6 SHORT NOTE 5M

Write a short note on hepatorenal syndrome.

General Medicine · Final Professional

Definition

Hepatorenal syndrome (HRS) is a form of functional, potentially reversible acute kidney injury occurring in advanced liver disease with portal hypertension and ascites, in which the kidneys are structurally normal — a fact demonstrated by the observation that a kidney from a patient with HRS functions normally when transplanted into a recipient with normal liver function.

It is a diagnosis of exclusion, made only after other causes of renal failure have been ruled out.

PATHOPHYSIOLOGY — a logical chain worth reproducing in an answer

1. Portal hypertension → release of nitric oxide and other vasodilators → splanchnic arterial vasodilatation

2. → fall in effective arterial blood volume despite total body fluid overload

3. → activation of the renin–angiotensin–aldosterone system, sympathetic nervous system and ADH

4. → intense renal vasoconstriction with reduced renal blood flow and glomerular filtration

5. → sodium and water retention, worsening ascites, and progressive renal failure

Additionally, systemic inflammation and bacterial translocation (particularly with SBP) and cirrhotic cardiomyopathy (an inadequate cardiac output response) contribute — which is why infection is the commonest precipitant.

Classification

TypeCoursePrecipitantPrognosis
HRS–AKI (formerly type 1)Rapidly progressive — doubling of creatinine within 2 weeksOften SBP, gastrointestinal bleeding, large-volume paracentesis without albumin, aggressive diuresisPoor — median survival of weeks without treatment
HRS–NAKI (formerly type 2)Slowly progressiveUsually spontaneousAssociated with refractory ascites; median survival months

Diagnostic Criteria

1. Cirrhosis with ascites (or acute liver failure)

2. Acute kidney injury by standard criteria

3. No improvement after 2 days of diuretic withdrawal AND volume expansion with intravenous ALBUMIN — this step is both diagnostic and therapeutic, and is what distinguishes HRS from pre-renal azotaemia

4. Absence of shock

5. No current or recent nephrotoxic drugs (NSAIDs, aminoglycosides, contrast)

6. No structural kidney disease — proteinuria < 500 mg/day, no microhaematuria, normal renal ultrasound

Characteristic urinary findings — reflecting intense sodium avidity with intact tubules:

  • Urine sodium very low (< 10 mEq/L)
  • Fractional excretion of sodium < 1%
  • Urine osmolality > plasma osmolality
  • Bland urinary sediment — no casts, no significant proteinuria (in contrast to acute tubular necrosis, which shows muddy brown granular casts and a high urine sodium)

Differential Diagnosis of Renal Failure in Cirrhosis

CauseDistinguishing features
Pre-renal azotaemiaRESPONDS to volume expansion; low urine sodium; history of diuresis, diarrhoea, bleeding
Hepatorenal syndromeDoes not respond to volume expansion; very low urine sodium; bland sediment
Acute tubular necrosisHigh urine sodium (> 40), FENa > 2%, muddy brown granular casts; history of shock, sepsis or nephrotoxins
GlomerulonephritisProteinuria, haematuria, red cell casts; associated with hepatitis B and C
Post-renal obstructionDilated system on ultrasound

Management

1. Prevention — far more effective than treatment

  • Albumin infusion with large-volume paracentesis (for taps over about 5 litres).
  • Albumin with antibiotics in spontaneous bacterial peritonitis — this specifically reduces the incidence of HRS and improves survival, and is one of the best-evidenced interventions in hepatology.
  • Avoid nephrotoxins — NSAIDs, aminoglycosides, contrast; avoid ACE inhibitors and ARBs in advanced cirrhosis.
  • Careful diuretic use with monitoring; avoid over-diuresis.
  • Antibiotic prophylaxis in high-risk patients (low ascitic protein, previous SBP, gastrointestinal bleeding).

2. General measures on presentation

  • Withdraw all diuretics and nephrotoxic drugs.
  • Volume expansion with intravenous albumin — both diagnostic and therapeutic.
  • Identify and treat precipitants — especially infection; perform a diagnostic ascitic tap and take cultures; treat gastrointestinal bleeding.
  • Monitor fluid balance, weight, electrolytes and renal function closely.

3. Specific pharmacological therapy

  • TERLIPRESSIN with intravenous ALBUMIN — the treatment of choice. Terlipressin is a splanchnic vasoconstrictor that reverses the splanchnic vasodilatation at the root of the syndrome, restoring effective arterial volume; albumin expands the volume and binds inflammatory mediators. Watch for ischaemic complications (digital, cardiac, mesenteric) and hyponatraemia.
  • Alternatives where terlipressin is unavailable: noradrenaline with albumin (requiring intensive care), or midodrine with octreotide and albumin.

4. Renal replacement therapy — as a bridge to transplantation or where there is a reversible precipitant; it does not alter the natural history in the absence of transplantation.

5. TIPS — may improve renal function in selected patients with preserved liver function, but risks encephalopathy.

6. LIVER TRANSPLANTATION — the only definitive treatment. All patients with HRS should be assessed urgently for transplantation, since HRS reflects end-stage liver disease and carries a very poor prognosis without it. Combined liver–kidney transplantation is considered where renal failure has been prolonged.

DANGER / REMEMBER

Hepatorenal syndrome is a diagnosis of exclusion, and the commonest error is to make it too quickly. Before accepting it, you must stop the diuretics, give a proper albumin volume challenge, look actively for infection with a diagnostic ascitic tap, review every drug for nephrotoxicity, and examine the urinary sediment. Many patients labelled with HRS in fact have reversible pre-renal failure or acute tubular necrosis, which have entirely different treatments and much better outcomes — and the label itself risks a nihilistic approach to a treatable problem.

All questions in Hepatology / GIT

  1. Q1Discuss the aetiology, serology, clinical features, complications and management of viral hepatitis. ★
  2. Q2Discuss the aetiology, clinical features, complications, investigations and management of cirrhosis of the liver. ★
  3. Q3Discuss the causes, clinical assessment and management of upper gastrointestinal bleeding. ★
  4. Q4Discuss the aetiology, clinical features, severity assessment, complications and management of acute pancreatitis. ★
  5. SN1Write a short note on the approach to jaundice and interpretation of liver function tests.
  6. SN2Write a short note on acute liver failure.
  7. SN3Write a short note on non-alcoholic fatty liver disease and alcoholic liver disease.
  8. SN4Write a short note on portal hypertension and ascites.
  9. SN5Write a short note on hepatic encephalopathy.
  10. SN6Write a short note on hepatorenal syndrome.
  11. SN7Write a short note on spontaneous bacterial peritonitis and secondary peritonitis.
  12. SN8Write a short note on amoebiasis — intestinal and hepatic.
  13. SN9Write a short note on Wilson's disease.
  14. SN10Write a short note on the clinical approach to hepatomegaly and splenomegaly.
  15. SN11Write a short note on peptic ulcer disease, Helicobacter pylori and Zollinger-Ellison syndrome.
  16. SN12Write a short note on gastro-oesophageal reflux disease.
  17. SN13Write a short note on chronic diarrhoea and malabsorption.
  18. SN14Write a short note on inflammatory bowel disease.
  19. SN15Write a short note on acute infective diarrhoea — cholera and bacillary dysentery.
  20. SN16Write a short note on lower gastrointestinal bleeding.

Every General Medicine chapter →

Scroll to Top